These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1561227)

  • 21. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours.
    MacCallum J; Cummings J; Dixon JM; Miller WR
    Br J Cancer; 2000 May; 82(10):1629-35. PubMed ID: 10817496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microbial transformations of isocupressic acid.
    Lin SJ; Rosazza JP
    J Nat Prod; 1998 Jul; 61(7):922-6. PubMed ID: 9677275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of tamoxifen and metabolites in human male urine by GC/MS.
    Mihailescu R; Aboul-Enein HY; Efstatide MD
    Biomed Chromatogr; 2000 May; 14(3):180-3. PubMed ID: 10850622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and distribution in the rat of acidic metabolites of tamoxifen.
    Ruenitz PC; Nanavati NT
    Drug Metab Dispos; 1990; 18(5):645-8. PubMed ID: 1981714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medication use, tamoxifen (TAM), and TAM metabolite concentrations in women with breast cancer.
    Gallicchio L; Tkaczuk K; Lord G; Danton M; Lewis LM; Lim CK; Flaws JA
    Cancer Lett; 2004 Jul; 211(1):57-67. PubMed ID: 15194217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient.
    Robinson SP; Langan-Fahey SM; Johnson DA; Jordan VC
    Drug Metab Dispos; 1991; 19(1):36-43. PubMed ID: 1673419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Isolation, identification and naringin biotransforming properties of naringinase producing bacteria isolated from human intestinal microflora].
    Chen J; Meng J; Wang Y; Wang X
    Wei Sheng Wu Xue Bao; 2014 Nov; 54(11):1323-32. PubMed ID: 25752139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods.
    Schild LJ; Phillips DH; Osborne MR; Hewer A; Beland FA; Churchwell MI; Brown K; Gaskell M; Wright E; Poirier MC
    Mutagenesis; 2005 Mar; 20(2):115-24. PubMed ID: 15755801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microbial transformations and 13C-NMR analysis of colchicine.
    Hufford CD; Collins CC; Clark AM
    J Pharm Sci; 1979 Oct; 68(10):1239-43. PubMed ID: 512852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients.
    Poon GK; Chui YC; McCague R; Lłnning PE; Feng R; Rowlands MG; Jarman M
    Drug Metab Dispos; 1993; 21(6):1119-24. PubMed ID: 7905393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biotransformation of celecoxib using microbial cultures.
    Srisailam K; Veeresham C
    Appl Biochem Biotechnol; 2010 Apr; 160(7):2075-89. PubMed ID: 19898964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolite induction via microorganism co-culture: a potential way to enhance chemical diversity for drug discovery.
    Bertrand S; Bohni N; Schnee S; Schumpp O; Gindro K; Wolfender JL
    Biotechnol Adv; 2014 Nov; 32(6):1180-204. PubMed ID: 24651031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its alpha-hydroxy and alpha,4-dihydroxy derivatives.
    Notley LM; Crewe KH; Taylor PJ; Lennard MS; Gillam EM
    Chem Res Toxicol; 2005 Oct; 18(10):1611-8. PubMed ID: 16533026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microbial Bioconversion: A Regio-specific Method for Novel Drug Design and Toxicological Study of Metabolites.
    Yousuf M; Jamil W; Mammadova K
    Curr Pharm Biotechnol; 2019; 20(14):1156-1162. PubMed ID: 31258075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biotransformations of the cardiovascular drugs mexrenone and canrenone.
    Preisig CL; Laakso JA; Mocek UM; Wang PT; Baez J; Byng G
    J Nat Prod; 2003 Mar; 66(3):350-6. PubMed ID: 12662091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
    Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
    Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
    Lim YC; Desta Z; Flockhart DA; Skaar TC
    Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days.
    Schild LJ; Divi RL; Beland FA; Churchwell MI; Doerge DR; Gamboa da Costa G; Marques MM; Poirier MC
    Cancer Res; 2003 Sep; 63(18):5999-6003. PubMed ID: 14522927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Production of long-chain hydroxy fatty acids by microbial conversion.
    Cao Y; Zhang X
    Appl Microbiol Biotechnol; 2013 Apr; 97(8):3323-31. PubMed ID: 23494626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Species differences in metabolism of panomifene, an analogue of tamoxifen.
    Monostory K; Jemnitz K; Vereczkey L; Czira G
    Drug Metab Dispos; 1997 Dec; 25(12):1370-8. PubMed ID: 9394026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.